Sciety strengthens board with Tommi Unkuri – partner at Summa Equity

Report this content

Tommi Unkuri was appointed a new member of the board of Sciety AB at the general meeting held on June 13th. With extensive experience in building and developing companies within finance and investing in unlisted life science companies, Unkuri is a valuable addition to the board.

Tommi Unkuri is a partner and co-founder of Summa Equity, a private equity company with a strong impact focus where he has established Changing Demographics, an investment area centred on healthcare and life science. Summa Equity manages assets totalling SEK 40 billion and pursues operations in both Europe and the USA. Unkuri has previously worked at Nordic Capital and Morgan Stanley. 

“I’ve been following Sciety for many years, and I’ve made several investments together with Sciety. Now it’s with great enthusiasm that I look forward to working with the Sciety team in my role as a board member. Sciety is a prominent company that plays an important role in the Nordic life science investment ecosystem. I particularly appreciate their ability to combine a business approach with the desire to make a difference, as well as the fact that clinical relevance is a given part of the selection process,” says Unkuri.

Andreas Lindblom, Managing Partner at Sciety, comments: “We’re extremely pleased to be welcoming Tommi Unkuri to Sciety’s board of directors. Tommi’s extensive experience of investments within life science and of building and developing operations within finance will be of immense value to Sciety, both within our existing operations and our business development projects.”

For more information, please contact:

Andreas Lindblom, Managing Partner, Sciety:, phone 070-375 73 73.

About Sciety

Sciety is a leading investment company, committed to supporting the growth of innovative life science and health tech companies in the Nordic region. We invest alongside Sciety Venture Partners, comprising family offices and private investors, as well as venture capital firms. Our mission is to enable the full potential of life science innovations, helping to bring breakthroughs in healthcare to people all over the world.